S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet

Sage Therapeutics (SAGE) Stock Price, News & Analysis

$21.86
+0.38 (+1.77%)
(As of 03/1/2024 ET)
Today's Range
$21.42
$22.17
50-Day Range
$21.13
$26.95
52-Week Range
$16.51
$59.99
Volume
803,586 shs
Average Volume
1.06 million shs
Market Capitalization
$1.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.71

Sage Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
90.8% Upside
$41.71 Price Target
Short Interest
Bearish
18.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.51
Upright™ Environmental Score
News Sentiment
1.00mentions of Sage Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.26) to ($4.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.31 out of 5 stars

Medical Sector

151st out of 950 stocks

Pharmaceutical Preparations Industry

62nd out of 438 stocks


SAGE stock logo

About Sage Therapeutics Stock (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock Price History

SAGE Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
SAGE Jan 2025 30.000 put
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
SAGE Therapeutics, Inc. Q4 Loss decreases, beats estimates
Sage Therapeutics Q4 2023 Earnings Preview
Sage Therapeutics Inc
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/03/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SAGE
Employees
689
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.71
High Stock Price Target
$294.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+90.8%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
16 Analysts

Profitability

Net Income
$-541,490,000.00
Net Margins
-626.32%
Pretax Margin
-626.33%

Debt

Sales & Book Value

Annual Sales
$86.46 million
Book Value
$13.30 per share

Miscellaneous

Free Float
56,801,000
Market Cap
$1.31 billion
Optionable
Optionable
Beta
0.87
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report














SAGE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 14 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price target for 2024?

16 analysts have issued 12-month target prices for Sage Therapeutics' stock. Their SAGE share price targets range from $20.00 to $294.00. On average, they predict the company's share price to reach $41.71 in the next twelve months. This suggests a possible upside of 90.8% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2024?

Sage Therapeutics' stock was trading at $21.67 on January 1st, 2024. Since then, SAGE shares have increased by 0.9% and is now trading at $21.86.
View the best growth stocks for 2024 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.28) by $0.73. The biopharmaceutical company had revenue of $77.97 million for the quarter, compared to analysts' expectations of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative trailing twelve-month return on equity of 54.41%. The business's quarterly revenue was up 2621.5% on a year-over-year basis. During the same period in the prior year, the business posted ($2.47) earnings per share.

What ETFs hold Sage Therapeutics' stock?
What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.86%), RTW Investments LP (8.66%), Palo Alto Investors LP (1.65%), Dimensional Fund Advisors LP (1.61%), Northern Trust Corp (0.90%) and Price T Rowe Associates Inc. MD (0.80%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAGE) was last updated on 3/3/2024 by MarketBeat.com Staff